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Corticotropin-releasing hormone microinfusion 
in the central amygdala diminishes a cardiac parasympathetic outflow 
under stress-free conditions 
A.  Wiersma,  B.  Bohus  and  J .M .  Koo lhaas  
Department of Animal Physiology, Centre for Behavioural, Cognitive and Neuro-Sciences, University of Groningen, Haren (The Netherlands) 
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The central nucleus of the amygdala (CeA) is known to be involved in the regulation of autonomic, neuroendocrine and behavioural responses in
stress ituations. The CeA contains large numbers of corticotropin-releasing hormone (CRH) cell bodies. Neuroanatomical studies revealed that 
the majority of the CRH fibres from the CeA have direct connections with autonomic regulatory nuclei in the brainstem. In the present study, 
the effects of locally infused CRH (30 ng) into the CeA, in freely moving male Wistar rats under stress-free conditions, were examined. Heart 
rate, endocrine parameters and behavioural ctivity were repeatedly measured before, during and after local administration f CRH, pretreated 
with either artificial CSF or the CRH-receptor antagonist, a-helical CRH (a-hCRH). CRH infusion alone caused a long-lasting increase in heart 
rate without affecting plasma drenaline and noradrenaline asindicators of sympathetic activity. This CRH-induced tachycardia was effectively 
blocked by pretreatment with a high dose (1 ~g) a-hCRH locally into the CeA, while the pretreatment with low dose (0.1 /zg) of the a-hCRH 
caused a minor blockade of the CRH-induced tachycardia. The results suggest hat CRH mechanisms in the CeA regulate the autonomic 
changes probably only by affecting parasympathetic butnot sympathetic output systems. Because CRH is given at the level of the cell body of the 
CRH neurons in the CeA, we suggest that the reduction of the parasympathetic output may be explained as an autoreceptor-mediated inhibition 
of CRH neurons from the CeA with parasympathetic-regulating brainstem nuclei. 
INTRODUCTION 
Cort icotropin-re leas ing hormone (CRH),  a 41- 
amino-acid pept ide,  is known to exert activating effects 
on the hypothalamus-p i tu i tary-adrenal  axis,by releas- 
ing adrenocort icotropin  24'51'67. In addit ion,  CRH is in- 
volved in the central  regulat ion of autonomic and be- 
havioural  activity. Numerous studies on the effects 
of intracerebroventr icu lar  (i.c.v.) CRH injections re- 
vealed overal l  increases in sympathet ic -mediated re-
sponses, l ike rises in heart  rate and blood pres- 
sure 13'29'42'44, rises in catecholamine and glucose lev- 
els 2'13'14'42'44 and increases in behavioura l  activ- 
ity 7'10'12'22'32'42'47'50'60'61'63'69'70. However,  CRH in the 
CNS also inhibits the cardiac parasympathet ic  nervous 
tone 26-28. The exact anatomical  sites responsible for 
the behavioural  and cardiovascular actions of central ly 
administered CRH are unknown yet. 
CRH immunoreact ive neurons and terminals are 
widely distr ibuted throughout he central  nervous sys- 
tem 24'5t'64. Among the forebrain regions that contain 
CRH- immunoreact ive  neurons are the PVN, the cen- 
tral nucleus of the amygdala (CeA)  and the bed nu- 
cleus of the stria terminal is (BNST). The CeA contains 
the majority of the forebrain CRH- immunoreact ive  
neurons that innervate the bra instem nuclei such as the 
parabrachia l  nucleus, midbra in central  grey and dorsal  
vagal complex 18'33'34'36. From the CeA, CRH has only 
efferent pathways to the bra instem areas, no ascending 
CRH neurons from the bra instem nuclei to the CeA 
are found to date 33. 
The CeA is an important  part  of the neural  circuitry 
mediat ing behavioural ,  autonomic and neuroendocr ine 
adjustments to environmental  stimuli 35. Numerous 
studies revealed that it is involved in the parasympa-  
thetic regulat ion of both the acute and the condit ioned 
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stress response. For example, bilateral CeA lesions 
attenuate the conditioned stress-induced, vagus-media- 
ted gastric ulceration in rats 38'39. In addition, lesioning 
of the CeA causes a disruption of the characteristic 
parasympathetic and passive coping responses; uch as 
bradycardia together with immobile behaviour, evoked 
by both conditioned 4°'55'68 and unconditioned aversive 
footshocks 56. 
The present study was designed to investigate the 
effects of CRH, infused into the CeA, on behaviour, 
cardiac and endocrine responses in basal, non-stressed 
conditions. In view of the involvement of the CeA in 
the parasympathetic output and the CRH connections 
to the brainstem vagal complex, it is likely that CRH 
peptidergic regulation in the CeA is involved in the 
regulation of the parasympathetic cardiovascular out- 
put and the behavioural components associated with 
passive coping response. The CRH-receptor antago- 
nist, a-helical CRH (a-hCRH) 9-41, was used to test 
the specificity of the observed exogenous CRH effects. 
MATERIALS  AND METHODS 
Animals 
Nineteen male Wistar rats, weighing 304-340 g at the beginning 
of the experiment, were used. The animals were housed individually 
in perspex cages (25 x 25 x 30 cm) and kept in a temperature con- 
trolled room (20 + 2°C) with a 12-h l ight-dark cycle (lights on from 
08.30 to 20.30 h). The experiments were performed uring the light 
period of the cycle (between 10.00 and 15.30 h). Food and water 
were available ad libitum. 
Surgery 
Each experimental animal was first provided with a permanent 
silicon catheter (0.95 mm o.d., 0.50 mm i.d.) in the right atrium, 
inserted via the right jugular vein. This method allows frequent blood 
sampling in undisturbed, freely moving rats 62. Bilateral permanent 
stainless-steel brain cannulae (o.d. 0.3 mm, i.d. 0.15 mm) for drug 
infusion were aimed just above the central amygdala (coordinates: 
6.7 mm rostral to interaural, lateral 4.0 mm to the midline and 
ventral 6.2 mm below the dura) according to Paxinos and Watson 52. 
Together with the heart catheter, the brain cannulae were perma- 
nently fixed to the skull of the rat by means of stainless-steel screws 
and dental cement. In order to record the electrocardiogram (ECG), 
transcutaneous steel electrodes made of standard paperclips were 
implanted, one between the scapulae and the other in the middle of 
the back s . The animals were kept under ether anaesthesia during the 
entire surgical procedure. 
Drug treatment 
Synthetic ra t /human CRH (CRF; Sigma Chemical Co., St. Louis, 
MO) and the CRH receptor antagonist, a -hCRH 9-41 (a-hCRF; 
Sigma Chemical Co., St. Louis, MO) were dissolved in artificial 
cerebrospinal f uid (aCSF) with ascorbic acid (100 /zg/ml  aCSF). 
CRH was administered in a dose of 30 ng/ rat  per cannula, as in a 
pilot-experiment, in which two lower doses of CRH, 3 ng and 300 pg, 
were tested, under the same conditions as described in this paper, no 
change in heart rate and behavioural response was found. 
a -hCRH was administered in doses of 0.1 /zg (low dose) and 1 
/zg/rat  (high dose) per cannula. The vehicle was sterile aCSF con- 
taining (in mM): NaC1 127.64, KCI 2.55, CaCI 2 1.26 and MgC12.6H20 
0.93. 
All compounds were infused in a total volume of 1 /zl in each 
brain cannula during a 7-min period. 
ECG recording and analysis 
The ECG of freely moving rats was monitored telemetrically by 
means of a miniature FM transmitter (EDB-ROY, Haren, The 
Netherlands) as described earlier s. The transmitter was connected to 
the transcutaneous electrodes and secured around the chest of the 
rat by means of a strap. The transmitted signals were received on a 
commercial FM radio and stored on tape. For off-line analysis, the 
recorded ECG samples were processed through a cardiotachometer 
pulse generator which generated a square wave pulse at each R wave 
(Olivetti, M24). The time between the onset of two consecutive 
pulses, the interbeat interval (IBI), was measured within the range of 
100 to 220 ms. IBI's were recalculated in beats/min.  
Blood sampling 
Before the start of the experiment, he animals were habituated 
to the full experimental procedure for at least 3 days. Fifty minutes 
before the start of an experiment, he animals were connected to a 
polyethylene blood-sampling tube. Blood samples of 0.3 ml were 
withdrawn for determination of plasma catecholamines and corticos- 
terone concentrations. Samples were immediately transferred to 
chilled (0°C) centrifuge tubes containing 0.01% EDTA as antioxi- 
dant, and 10 /xl heparin solution (500 IU /ml )  as anticoagulant. 
Blood was centrifuged at 4°C for 10 min at 5000 rpm. The super- 
natant was stored at -70°C.  Withdrawn blood was replaced by 
transfusion of heparinized donor blood, after each blood sample 
taken, in order to minimize the changes in blood volume. Donor 
blood was obtained from unstressed rats of the same strain also 
provided with permanent heart catheters. 
Plasma catecholamine determination was performed by high-per- 
formance liquid chromatography (HPLC) with electrochemical deter- 
mination (ECD) as described earlier 56. Plasma corticosterone was 
measured by means of reversed-phase HPLC according to the method 
of Dawson TM with minor modifications. Samples were redissolved in 
ultra-pure water and spin-filtered through a 0.2-/xm membrane filter 
(Millipore) before detection. 
Behauioural measurements 
Behaviour was recorded on the basis of the following criteria: 
resting/sleeping = inactive with eyes open or closed; immobility = 
completely motionless, absence of skeletal and vibrissae movements 
except hose associated with respiration; exploring = investigation of 
any part of the home cage; grooming = wiping the fur with forepaws 
and tongue (washing); burying = pushing the bedding material with 
rapid movements of the snout or forepaws; rearing = sniffing in the 
air with both forepaws from the floor; eating = chewing food pellets 
or faeces; sniffing = sniffing in the air with paws on the floor. 
All behavioural elements were recorded by means of a keyboard- 
operated microprocessor (EDB, Haren, The Netherlands). The dura- 
tion and the frequency of these elements were recorded and ex- 
pressed as the percentage of the total observation period. 
Experimental procedures 
The experiments were performed in the animals' home cages 
under stress-free conditions. The rats were habituated to the strap 
holding of the transmitter, and to the infusion and blood-sampling 
procedure for a few hours during 3 days before the start of the 
experiments. After 10 or more days recovery from surgery, the rats 
were tested for the first time. A cross-over design was used in which 
each rat served as its own control. Each animal was pretreated either 
with a -hCRH or vehicle, 50 min before CRH or aCSF infusion. The 
experimental protocol is given in Table I. 
Each animal received vehicle and CRH infusion after vehicle 
pretreatment and either one of the pretreatment dose of a -hCRH 
(Table I). Each treatment was separated by a wash-out period of at 
least 1 week. The pretreatment was given at t = -50  min at the lap 
of the experimentor. Immediately after the pretreatment, the rat was 
placed into its home-cage, connected with ECG transmitter, blood 
sampling and infusion tubes, filled with the second drug infusion 
solution. Immediately after the second control sample, at t = 0 min, 
either the CRH or aCSF was microinfused in the undisturbed, freely 
moving rat. Each 1-min sample of heart rate and behaviour was 
directly followed by a blood sample, before (t =-  10 and t =-  1 
min), during (t = 3 and t = 6 min) and after the second microinfu- 
sion (t = 8, 10, 12, 17, 27, 47, 67 min). Corticosterone was deter- 
mined in all blood samples. Noradrenaline and adrenaline were 
determined in the blood samples taken at t = - 1, 6, 12, and 47 min. 
Histology 
At the end of the experiments, the rats were deeply anaes- 
thetized with sodium pentobarbital (90 mg/kg i.p.) and perfused 
intracardially with saline followed by a 4% formaldehyde solution. 
The brains were postfixed in the same fixative for at least 1 week. 
Frozen sections of 40 /zm were cut, and the tip of the cannula 
placement was determined on unstained sections. 
Statistics 
Cardiac, hormonal and behavioural data were evaluated using an 
analysis of variance with repeated measures (ANOVA) and followed 
by the correlated Student t-test. A probability level of P < 0.05 was 
taken as significant for all tests. 
RESULTS 
Histology 
Histological examination revealed that four of the 
animals had to be excluded from further analysis be- 
cause of improper bilateral cannulae placement. The 
cannulae tips had to be localized just above or entering 
the dorsal edge of the CeA. Fig. 1 shows examples of 
cannulae placements that were considered as proper 
(e) and improper (o) bilateral CeA placements. 
Cardiac responses 
Fig. 2 shows that local infusion of 30 ng of CRH in 
the CeA produced an increase in heart rate response 
compared to the vehicle-treated group. The tachycar- 
dia started during the infusion and lasted for the entire 
registration period. The ANOVA showed a significant 
main effect of t reatment  (Fl.17 = 11.823, P<0.005)  
and an interaction between treatment and time (F4.68 
= 4.309, P < 0.005). The CRH-induced tachycardia was 
reduced by the CRH-receptor antagonist in high dose 
(1 /zg), and partially reduced by the low dose of the 
a-hCRH (0.1 /zg) (Fig. 2). Comparing the high dose 
TABLE I 
The experimental microinfusion schedule into the central nucleus o f  the 
amygdala 
Test Pretreatment Treatment 
t = - 50 min t = 0 rain 
1 aCSF aCSF 
2 aCSF CRH (30 ng) 
3a a-hCRH 1.0/zg CRH (30 ng): high dose 
3b a-hCRH 0.1/xg CRH (30 ng): low dose 
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Fig. 1. Schematic drawing of coronal section of the rat brain at 6.7 
mm rostral to interaural showing the tips of representative good 
bilateral CeA cannulae placements (o). The open rounds indicate 
improper bilateral cannulae placements (<3). 
a-hCRH + CRH-treated group with the vehicle-treated 
group, the ANOVA revealed a significant interaction 
effect (F4.s6 = 3.285, P < 0.05). Analysis of the separate 
sample times revealed one significant difference in 
heart rate response between the high dose a-hCRH + 
CRH infusion and the vehicle-group (at t = 6 min). No 
significant differences were found between the vehicle 
and the low dose a-hCRH + CRH group, and between 
the CRH and the low dose a-hCRH + CRH group. 
Catecholamine r sponse 
Fig. 3 shows the plasma adrenaline (Fig. 3a) and 
noradrenaline (Fig. 3b) levels in the four groups be- 
fore, during and after the second infusion. No response 
was seen in both catecholamines on the infusion of 
CRH or the vehicle in all the four groups (Fig. 3). 
Analysis of variance did reveal neither a significant 
treatment effect nor treatment × time interaction be- 
tween the four groups. 
Corticosterone r sponse 
No significant differences in plasma corticosterone 
between the vehicle and CRH-group were found (Fig. 
4). The corticosterone l vels of both groups stayed on 
the same level after either drug or vehicle treatment. 
However in the a-hCRH + CRH infusion groups, sig- 
nificant differences were found in relation to the vehi- 
cle group and the CRH group. Both doses of the 
antagonist + CRH treatment revealed slowly rises in 
corticosterone l vels, which reach their maximum at 
the last sample. The a-hCRH in high dose compared 
to the CRH group showed a significant effect (F1.17 = 
6.444, P < 0.05) and a significant ime effect (Fa,6s = 
8.5222, P < 0.0001). The Student t-test indicated that 
only at t -  17 and t = 27 min significant differences 
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Fig. 2. Changes in heart rate (+ S.E.M.) as a consequence of infusion 
of CRH (30 ng in 1 p-l) or artificial-CSF (1 p-l) for 7 min at t = 0 min 
into the CeA and pretreated with aCSF (1 p-l) or a-hCRH high dose 
(1 p-g in 1 p.1) or low dose (0.1 p-g in 1 p-l) at t = -50  into the CeA 
in stress-free situations. The infusion period is indicated by the 
horizontal bar. CRH-group, n = 14 (e); vehicle-group, n = 13 (o); 
a-hCRH + CRH group high dose (1.0 p-g, n = 8 ( zx ); a-hCRH + CRH 
group low dose (0.1 p-g), n = 6 (A). 
were found between the high dose a-hCRH + CRH 
and the CRH-treatment. The low dose a -hCRH + 
CRH group showed significant increases in corticos- 
terone level compared to both the vehicle and the 
CRH groups (vehicle-a-hCRH + CRH (0.1 /xg), treat- 
ment: FI.13 = 6.664, P < 0.05; time: F4.52 = 12.353, P < 
0.0001; treatment × time: F4.52 = 3.703, P < 0.01; 
CRH-a-hCRH + CRH (0, 1 /*g), treatment: F1.17 = 
6.444, P < 0.05; time: F4.68 = 8.522, P < 0.001; treat- 
ment x time F4.68 = 24.498, P < 0.08). The data at t = 
17 and t = 27 min demonstrated significant increases 
between the low dose a-hCRH + CRH and the vehicle 
and the CRH-group. 
Behavioural responses 
Resting / sleeping 
Resting or sleeping is the major element he animals 
displayed uring the experiments, the other behaviours 
appeared more rarely. 
Resting behaviour in the vehicle group remained at 
a constant level, during the whole experiment (Fig. 5a). 
Infusion of CRH in both the CRH and the high dose 
a -hCRH + CRH group resulted in a reduction in rest- 
ing behaviour (Fig. 5a). Comparison between the vehi- 
cle the CRH group, and the high dose a-hCRH + CRH 
group revealed significant treatment effects (aCSF- 
CRH, FI.27 = 5.234, P < 0.05; aCSF-a-hCRH + CRH 
(1 Ixg), F~.21 = 4.137, P < 0.05), no time or treatment X
time interaction effects were found. At t = 6 min the 
duration of resting was significantly reduced in rats 
receiving the a -hCRH + CRH and CRH treatments, 
compared to the vehicle group. The reduction in rest- 
ing behaviour lasted until the infusion period was 
stopped, after which it slowly returned to basal level (at 
t = 27). The results of resting behaviour in the low dose 
a-hCRH + CRH group are not shown, as no differ- 
ences between this group and the vehicle-group were 
found. 
Immobility 
No effects of the infusion of either aCSF or CRH 
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Fig. 3. Plasma adrenaline (A) and noradrenaline (B) levels before, during and after microinfusion into the CeA of CRH pretreated with 
artificial-CSF (CRH), CRH pretreated with a-hCRH, high dose (hCRH + CRH 1 p-g), or CRH pretreated with a-hCRH, low dose (hCRH + CRH 
0.1 p.g) in stress-free conditions. In the control experiments, artificial CSF pretreated with aCSF was infused (CSF). Data are expressed as 
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Fig. 4. Plasma corticosterone levels before, during and after microin- 
fusion into the CeA of CRH pretreated with artificial-CSF (CRH), 
CRH pretreated with a-hCRH, high dose (hCRH + CRH 1 /~g), or 
CRH pretreated with a-hCRH, low dose (hCRH+CRH 0.1 /.~g) in 
stress-free conditions. In the control experiments, artificial CSF 
pretreated with aCSF was infused (CSF). Data are expressed as 
averages+S.E.M. The infusion period is indicated by the hori- 
zontal bar. 
the vehicle group the CRH group and the high dose 
a -hCRH + CRH group (Fig. 5b). Only in the CRH 
group and the low dose a -hCRH + CRH group, the 
level of immobi le behaviour  was overall  h igher com- 
pared to the vehicle group. Analysis of var iance re- 
vealed significant reatment  effects between the vehicle 
and the CRH-group (F1.27 = 9.029, P < 0.01) and the 
vehicle and the low dose a -hCRH + CRH group (F1.20 
= 9.211, P < 0.01). Signif icant t ime and t reatment  ×
time interact ions were found between the vehicle and 
the low dose a -hCRH + CRH group (time: F4.80 = 
9.733, P < 0.0001; interaction: F4.80 = 6.971, P < 0.001), 
CRH and low dose t~-hCRH + CRH group (time: F4.76 
= 4.858, P < 0.01; interaction: F4.76 = 2.502, P < 0.05) 
and between the two ~-hCRH + CRHgroups  (time: 
F4.52 = 3.937, P < 0.05; interaction: F4.52 = 3.051, P < 
0.05). The rats t reated with the low dose a -hCRH + 
CRH infusion showed a rapid increase in immobi le 
behaviour at t = 10 and t = 12, and a rapid recovery 
from immobil i ty after t = 12 (Fig. 5b). Significant dif- 
ferences were found between the vehicle group and the 
low dose a -hCRH + CRH group at t = 10 and t = 12, 
and the vehic le-group with the CRH-group at t = 3. 
The results of immobil i ty in the high dose a -hCRH + 
CRH group are not shown, as no dif ferences between 
this group and the vehicle group were found. 
Exploring 
Analysis of var iance revealed significant reatment  
× t ime interact ions between the veh ic le -CRH group 
(F4.108 = 2.334, P < 0.05) and the vehicle-high dose an- 
tagonist + CRH group (F4.48 = 2.911, P < 0.05) were 
found. The occurrence of explorat ion was significantly 
increased in the CRH and the high dose a -hCRH + 
CRH group at t =6 min compared  to the vehicle 
group. No effects were found between the CRH and 
the two a -hCRH + CRH groups. 
The occurrence of the other behavioural  responses, 
i.e. grooming, burying, rearing, sniffing and eating, did 
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Fig. 5. Time spent in various behaviours before, during and after microinfusion into the CeA of CRH pretreated with CSF (CRH-group), CRH 
pretreated with a-hCRH, high dose (hCRH+CRH 1 /zg), or CRH pretreated with t~-hCRH, low dose (hCRH+CRH 0.1 /zg) in stress-free 
conditions. In the control experiments, artificial CSF pretreated with aCSF was infused (CSF). Data are expressed as averages+ S.E.M. The 
infusion period is indicated by the horizontal bar. Resting (5A) and immobile (5B) behaviour are shown. 
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DISCUSSION 
The major finding of the present study is that local 
CRH microinfusions, into the CeA, increased heart 
rate without affecting plasma adrenaline, nora- 
drenaline and corticosterone concentrations in rats un- 
der stress-free conditions. Simultaneously, the be- 
haviours, immobility and exploring were increased. 
Pretreatment of the CRH-receptor antagonist resulted 
in a dose-dependent blockade of the CRH-induced 
tachycardia. However, pretreatment of the CRH-re- 
ceptor antagonist did not cause a blockade in the 
CRH-induced behavioural activation. In contrast with 
the CRH group, both CRH-receptor antagonist treat- 
ments showed an increase in corticosterone r sponse, 
while the catecholaminergic levels remained at a con- 
stant level. 
The results indicate that the CRH system in the 
CeA is involved in cardiovascular nd behavioural con- 
trol, whereas adrenal neuroendocrine mechanisms do 
not seem to be affected by CRH in the CeA in stress- 
free conditions. 
The obtained tachycardia by CRH infusion in the 
CeA can be explained by three possible mechanisms. A 
direct stimulation of the sympathetic output or a direct 
inhibition of the parasympathetic vagal output or indi- 
rectly by an increase in behavioural activity may be 
responsible for the rise in heart rate after CRH admin- 
istration. Indeed an increase in exploring is observed, 
which is considered to be accompanied by a rise in 
sympathetic outflow. Rises in plasma adrenaline and 
noradrenaline are generally taken as a measurement 
for the activation of the sympathetic nervous ystem 3~'58. 
No elevations in peripheral adrenaline and nora- 
drenaline levels were found as a consequence of the 
CRH-infusion. Compared to other experiments, the 
present plasma catecholamine l vels can be considered 
as basal values 20'58. Two conclusions can be drawn, first 
it can be concluded that the tachycardia is not the 
result of a general activation of the sympathetic ner- 
vous system. Rather, a reduction in the parasympa- 
thetic activity seems to be responsible for the CRH-in- 
duced increase in heart rate in stress-free conditions. 
Secondly, these low catecholamine l vels indicate that 
the experiment is carried out under stress-free condi- 
tions indeed. In conclusion, the balance in activity of 
the sympathetic and parasympathetic components of 
the autonomic nervous system seems to be altered by 
the CRH infusion, with a shift towards the sympathetic 
side. 
The corticosterone results revealed no leakage of 
infused CRH to the periphery, with subsequent activa- 
tion of the pituitary-adrenal axis, in the CRH group, as 
no increases in peripheral plasma corticosterone l vels 
during the infusion were found. These results are in 
agreement with other groups who asserted that the 
CeA does not seem to be involved in the regulation of 
plasma corticosterone in stress-free conditions 6,59. Al- 
though, the CeA seems to be involved in the corticos- 
terone response to different stress-situations ~,4'5,55,57,68. 
One group asserted that CRH mechanisms in the CeA 
seem to play an important role in the corticosterone 
response after stress 37. 
The basal plasma levels of corticosterone were 
slightly elevated in comparison to the usual mean 24 h 
average of 5 /zg/dl  2°. These slightly elevated basal 
levels of plasma corticosterone in all the groups cannot 
be a result of the animals being stressed at the begin- 
ning and during the experiments, as the behavioural 
data showed that during the experiment the rats were 
resting/sleeping during most of the time. 
The behavioural responses to CRH given in the 
CeA revealed some discrepancy with the behavioural 
responses observed after i.c.v. CRH injections. The 
decrease in resting behaviour, after CRH infusion in 
the CeA, was accompanied by an increase in ex- 
ploratory and immobility behaviour, but not by an 
increase in grooming. The increase in locomotor be- 
haviour 11"25'46'48'6°'65 and immobile behaviour 69 is in 
accordance with i.c.v. CRH reports. However, in this 
experiment no effect of locally applied CRH in the 
CeA on grooming behaviour was found, which disagree 
with the increase in grooming found after i.c.v. CRH 
infusion 7'9'12'22'24'42'43'50"69. Accordingly, regionally spe- 
cific neuromodulatory properties of CRH seem to play 
an important part in the different regulation of auto- 
nomic and behavioural responses in the CNS. This 
regional specificity of CRH was suggested earlier by 
Diamant and colleagues z3and Koob and co-workers 41. 
The present results differ in some respect from 
reports by other investigators injecting CRH locally in 
the amygdala rea 15'45'48. One group reported an eleva- 
tion of noradrenaline levels ~5, while another group 
asserted that the enhanced effect they found on mem- 
ory of aversive learning by infusion of CRH in the 
amygdala, was a result of activating the release of 
adrenaline by CRH 45,48. The discrepancy between these 
results and the results of the present study may be due, 
at least in part, to differences in volume injected, the 
concentration used, and the exact area of injection/ 
infusion of the peptide. Although the possibility of 
diffusion of CRH to adjacent responsive structures, as 
to the basolateral nucleus of the amygdala, has to be 
considered, the various CRH-induced responses at the 
CeA, such as the diminishing parasympathetic re- 
sponse, may indicate a site specificity for the CRH- 
evoked effects. 
The effects of CRH can be blocked by a local 
application of the a-hCRH, the CRH receptor antago- 
nist. This indicates that CRH receptors are involved. 
At the level of the CeA these CRH-binding sites may 
represent autoreceptors 21. As CRH is given at the level 
of the cell body of the CRH neurons in the CeA, the 
present data of an inhibition of the parasympathetic 
response may be explained by an autoreceptor-media- 
ted inhibition of CRH connections with the parasym- 
pathetic-regulating brainstem nuclei. This hypothesis 
supported by recent electrophysiological research by 
Rainnie and colleagues 53in which differential effects 
of CRH on the membrane properties of basolateral 
(BLA) and central amygdala (CeA) neurons in vitro 
was found. This group suggested that the differential 
action of CRH on the BLA and CeA neurons was 
caused by activation of a heterogenous population of 
CRH receptors in the amygdala. They proposed that 
the CRH-mediated inhibition in CeA neurons was due 
to an autoinhibition caused by somatodendritic CRH 
autoreceptors 53. 
Another possible explanation of the CRH-induced 
cardiovascular effects can be that CRH can act also on 
receptors located on neurons which do not contain 
CRH and project to structures which are involved in 
cardiovascular control, i.e. the lateral hypothala- 
mus 17'30'49. Uryu  and colleagues 66 have recently de- 
scribed, that part of the CRH axon terminals in the 
CeA arises from neurons in the lateral hypothalamic 
area and the dorsal raphe nucleus, the amygdalophetal 
pathway, and the others from intra-amygdaloid CRH 
neurons. Accordingly, the amygdalopethal and intra- 
amygdaloid pathways might participate in the regula- 
tion of autonomic responses and behavioural activa- 
tion, since both the lateral hypothalamic area 49 and the 
amygdala re considered to contribute to the organiza- 
tion of autonomic, somatosensoric and somatomotoric 
responses. 
The CRH receptor antagonist, a-hCRH, has been 
used in the present experiment only as a tool to 
demonstrate the specificity of the exogenous CRH 
administration. Some groups have described a partial 
agonistic effect of the CRH-receptor antagonist 7°. The 
transient agonistic activity of the ot-hCRH will not be 
detected when the o~-hCRH is injected 30 to 60 min 
before exposing the animal to a stressful stimulus, 
whereas binding of CRH, secreted in reaction to the 
stress or administered exogenously, to its receptor may 
still be adequately blocked 22. The apparent necessity to 
use the antagonist at large amounts points towards a 
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low affinity of the antagonist for the CRH recep- 
tor 7,16,24,43,65. 
The differences found between administration of 
the a-hCRH alone and as a pretreatment before a 
CRH infusion can have the following explanation. The 
CRH-receptor antagonist can probably block both the 
tonic (endogenous release of CRH), and the phasic 
(stress-related release, or exogenous administered) re- 
lease of CRH. In the present experiment, he phasic 
release of CRH, and the blockade by the antagonist, 
was examined, because infusion of CRH probably re- 
sulted in a raise in concentration of CRH in the 
synaptic lefts. While in the experiments of the other 
groups using a-hCRH alone mostly the blockade by 
a-hCRH of the tonic release of CRH, endogenous 
amount of CRH, was examined. Besides, it is suggested 
that the CRH-receptor antagonist can produce effects 
which are unrelated to its action at the CRH-receptor 7 
which can also be an explanation for the behavioural 
response seen after pretreatment bythe a-hCRH infu- 
sion. 
However, the possibility cannot be ruled out that 
the reduction in resting behaviour, the increase in 
exploration and the increase in plasma corticosterone 
by the combined a-hCRH and CRH infusion is due to 
possible partial agonistic properties of a-hCRH. An- 
other explanation for the additive effects of ~-hCRH 
+CRH compared to CRH may be the spread of 
a-hCRH to other adjacent responsive structures. 
Although some groups reported that the CRH and 
the a-hCRH interact with the same receptor popula- 
tion in a competitive manner 3, different receptor 
affinities to CRH and its antagonist may be another 
explanation for the results mentioned above, and have 
different affinities to CRH and its antagonist. 
Our results and earlier work done in this labora- 
tory 54 are consistent with the aforementioned state- 
ment that the CeA selectively regulates the parasympa- 
thetic output of acute and conditioned stress re- 
sponses. The present results leads to the hypothesis 
that CRH at the level of the CeA inhibits parasympa- 
thetic output in non-stressed situations. This results in 
a shift in the balance in activity of the sympathetic and 
parasympathetic components of the autonomic nervous 
system towards the sympathetic side. Furthermore, it is 
hypothesized that mediation of CRH-autoreceptors on
the CRH neurons in the CeA, with connections to 
parasympathetic brainstem nuclei, can be responsible 
for the diminishing parasympathetic response found 
under stress-free conditions. To verify this hypothesis 
further esearch is necessary. 
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